Related references
Note: Only part of the references are listed.More Severe Erosive Phenotype Despite Lower Circulating Autoantibody Levels in Dipeptidyl Peptidase-4 Inhibitor (DPP4i)-Associated Bullous Pemphigoid: A Retrospective Cohort Study
Sascha Stander et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2021)
Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study
Gabor Suto et al.
BMJ OPEN DIABETES RESEARCH & CARE (2021)
Dipeptidyl-peptidaseIVinhibitors (DPP4i)-associated bullous pemphigoid: Estimating the clinical profile and exploring intraclass differences
Khalaf Kridin
DERMATOLOGIC THERAPY (2020)
The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in the elderly: a retrospective study
Zrinka Bukvic Mokos et al.
CROATIAN MEDICAL JOURNAL (2020)
Association Between Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors: A Retrospective Cohort Study
J. Magdaleno-Tapial et al.
ACTAS DERMO-SIFILIOGRAFICAS (2020)
Dipeptidyl peptidase 4 inhibitors linked bullous pemphigoid in patients with type 2 diabetes mellitus: A series of 13 cases
Alka Jha et al.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2020)
Dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients
Yohei Kawaguchi et al.
JOURNAL OF DIABETES INVESTIGATION (2019)
Epitope-spreading phenomena in dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid
I. Garcia-Diez et al.
BRITISH JOURNAL OF DERMATOLOGY (2019)
Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General Population
Marthe Plaquevent et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)
Association of Dipeptidyl Peptidase 4 Inhibitor Use With Risk of Bullous Pemphigoid in Patients With Diabetes
Seon Gu Lee et al.
JAMA DERMATOLOGY (2019)
Assessment of the Prevalence of Mucosal Involvement in Bullous Pemphigoid
Khalaf Kridin et al.
JAMA DERMATOLOGY (2019)
Dipeptidyl peptidase IV inhibitor-associated bullous pemphigoid: a recently recognized autoimmune blistering disease with unique clinical, immunological and genetic characteristics
Wataru Nishie
IMMUNOLOGICAL MEDICINE (2019)
Gliptin-associated Bullous Pemphigoid and the Expression of Dipeptidyl Peptidase-4/CD26 in Bullous Pemphigoid
Outi Lindgren et al.
ACTA DERMATO-VENEREOLOGICA (2019)
Increased prevalence of diabetes mellitus in bullous pemphigoid patients during the last decade
L. Fania et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2018)
Detection of anti-BP180 NC16A autoantibodies after the onset of dipeptidyl peptidase-IV inhibitor-associated bullous pemphigoid: a report of three patients
Y. Mai et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Peripheral eosinophilia in bullous pemphigoid: prevalence and influence on the clinical manifestation
K. Kridin
BRITISH JOURNAL OF DERMATOLOGY (2018)
Unique clinical and serological features of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors
H. Horikawa et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors: A Disproportionality Analysis Based on the Japanese Adverse Drug Event Report Database
Masanori Arai et al.
DIABETES CARE (2018)
Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization
Irene Garcia-Diez et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2018)
Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid
Chika Chijiwa et al.
JOURNAL OF DERMATOLOGY (2018)
HLA-DQB1*03:01 as a Biomarker for Genetic Susceptibility to Bullous Pemphigoid Induced by DPP-4 Inhibitors
Hideyuki Ujiie et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
Vildagliptin Significantly Increases the Risk of Bullous Pemphigoid: A Finnish Nationwide Registry Study
Outi Varpuluoma et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
Oral diabetes medications other than dipeptidyl peptidase 4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study
Outi Varpuluoma et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Detection and characterization of IgG, IgE, and IgA autoantibodies in patients with bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors
Luca Fania et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland
Michael Benzaquen et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Commentary on 'Changing prevalence of diabetes mellitus in bullous pemphigoid: it is the dipeptidyl peptidase-4 inhibitors'
L. Fania et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2018)
Changing prevalence of diabetes mellitus in bullous pemphigoid: it is the dipeptidyl peptidase-4 inhibitors
A. Gravani et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2018)
Clinical and Immunological Profiles of 14 Patients With Bullous Pemphigoid Without IgG Autoantibodies to the BP180 NC16A Domain
Kenta Nakama et al.
JAMA DERMATOLOGY (2018)
Dipeptidyl Peptidase-4 Inhibitor-associated Bullous Pemphigoid: Recurrence with Epitope Spreading
Hiroyuki Takama et al.
ACTA DERMATO-VENEREOLOGICA (2018)
Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes Estimating the Risk of the New Agents and Characterizing the Patients
Khalaf Kridin et al.
JAMA DERMATOLOGY (2018)
Dipeptidyl-peptidase IV inhibitor-associated bullous pemphigoid: A systematic review and meta-analysis
Khalaf Kridin et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Bullous pemphigoid in patients with DPP-4 inhibitors at the onset of disease: does this differ from common bullous pemphigoid?
Aikaterini Patsatsi et al.
EUROPEAN JOURNAL OF DERMATOLOGY (2018)
Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors: A report of five cases
Satoshi Yoshiji et al.
JOURNAL OF DIABETES INVESTIGATION (2018)
The Growing Incidence of Bullous Pemphigoid: Overview and Potential Explanations
Khalaf Kridin et al.
FRONTIERS IN MEDICINE (2018)
Meeting Report of the Pathogenesis of Pemphigus and Pemphigoid Meeting in Munich, September 2016
Enno Schmidt et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2017)
Use of Dipeptidyl-Peptidase IV Inhibitors and Bullous Pemphigoid
Clara Schaffer et al.
DERMATOLOGY (2017)
Bullous Pemphigoid: A Review of its Diagnosis, Associations and Treatment
Philippe Bernard et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2017)
Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database
J. Bene et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system
C. Klemann et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2016)
Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database
M. Garcia et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2016)
Autoantibody Profile Differentiates between Inflammatory and Noninflammatory Bullous Pemphigoid
Kentaro Izumi et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2016)
Prevalence and Age Distribution of Pemphigus and Pemphigoid Diseases in Germany
Franziska Huebner et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2016)
Bullous Pemphigoid Associated With Linagliptin Treatment
Roger Haber et al.
JAMA DERMATOLOGY (2016)
Bullous pemphigoid induced by vildagliptin: a report of three cases
Johana Bene et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2015)
Increasing incidence of bullous pemphigoid in Northern Finland: a retrospective database study in Oulu University Hospital
A. -K. Forsti et al.
BRITISH JOURNAL OF DERMATOLOGY (2014)
Bullous Pemphigoid Autoantibodies Directly Induce Blister Formation without Complement Activation
Hideyuki Ujiie et al.
JOURNAL OF IMMUNOLOGY (2014)
Human Eosinophils Express the High Affinity IgE Receptor, FcεRI, in Bullous Pemphigoid
Kelly N. Messingham et al.
PLOS ONE (2014)
Bullous pemphigoid associated with dipeptidyl peptidase IV inhibitors. A case report and review of literature
Amy Attaway et al.
JOURNAL OF DERMATOLOGICAL CASE REPORTS (2014)
Incidence and Mortality of Bullous Pemphigoid in France
Pascal Joly et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2012)
Definitions and outcome measures for bullous pemphigoid: Recommendations by an international panel of experts
Dedee F. Murrell et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2012)
Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin
K. Skandalis et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2012)
Ectodomain Shedding Generates Neoepitopes on Collagen XVII, the Major Autoantigen for Bullous Pemphigoid
Wataru Nishie et al.
JOURNAL OF IMMUNOLOGY (2010)
Plasmin Plays a Role in the In Vitro Generation of the Linear IgA Dermatosis Antigen LADB97
Silke C. Hofmann et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2009)
Dipeptidyl peptidase IV (DPP IV/CD26) is a cell-surface plasminogen receptor
Mario Gonzalez-Gronow et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2008)
Inhibition of CD26/dipeptidyl CCL11/eotaxin-mediated recruitment peptidase IV enhances of eosinophils in vivo
Ulf Forssmann et al.
JOURNAL OF IMMUNOLOGY (2008)
Bullous pemphigoid and pemphigus vulgaris - incidence and mortality in the UK: population based cohort study
S. M. Langan et al.
BMJ-BRITISH MEDICAL JOURNAL (2008)
Elevated expression and release of tissue-type, but not urokinase-type, plasminogen activator after binding of autoantibodies to bullous pemphigoid antigen 180 in cultured human keratinocytes
E Schmidt et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2004)
Share Paper
